METAANALYSIS OF RESULTS FROM CLINICAL-TRIALS ON PREVENTION OF CORONARY HEART-DISEASE BY LIPID-LOWERING INTERVENTIONS

被引:0
|
作者
CUCHERAT, M
BOISSEL, JP
机构
关键词
CORONARY HEART DISEASE; PROPHYLAXIS; CHOLESTEROL-LOWERING TREATMENT; METAANALYSIS;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The efficacy of lipid-lowering interventions for the prevention of coronary heart disease (CHD) has been assessed in several clinical trials. A summary of the published results from controlled trials involving various primary and secondary preventive interventions has been performed using meta-analysis techniques. Non-randomized trials involving either multifactorial interventions or those no longer used in this indication were not included. Nineteen trials, with a total of 48 273 patients, were included in the analysis. The intervention assessed was a drug in 11 trials, a diet in seven others and surgery in the last. Seven trials involved primary prevention and the other 12 involved secondary prevention. The number of patients included per trial varied between 143 and 10 627 and the mean length of follow-up ranged from 0.9 to 9.7 years. At entry, the mean age varied between 45 and 59 years, and the mean serum cholesterol concentration varied between 6.05 and 7.78 mmol/l. The mean decrease in serum cholesterol concentration was between 0.28 and 2.70 mmol/l. The analysis, performed with the logarithm of the odds ratio (OR) method, with the level of significance set at 0.01, showed a significant decrease in the incidence of non-fatal myocardial infarction (MI) (14 trials; 30 370 patients; common OR = 0.75; p < 10(-3)). There was also a slight, significant reduction in the incidence of death due to CHD (15 trials; 39 175 patients; common OR = 0.88; p = 0.004), and no effect was observed on the incidence of death from all causes (16 studies; 47 005 patients; common OR = 0.99; p = 0.78). Non-significant increases in the incidence of death due to cancer (11 trials; 37 495 patients; common OR = 1.23; p = 0.057) and mortality not caused by illness (10 trials; 28 438 patients; common OR = 1.36; p = 0.10) were also noted. Heterogeneity testing was not significant at p = 0.05, for all criteria. The individual analysis on trials involving primary or secondary preventative treatment gave similar results. It remains unclear as to why the observed reduction in the incidence of CHD does not affect death from all causes. This may be due to either treatment or follow-up being too short, or there may be some unidentified toxic effects, although the meta-analysis did not show any significant differences in death caused by cancer or by accident.
引用
收藏
页码:109 / 129
页数:21
相关论文
共 50 条
  • [21] TRIALS OF CORONARY HEART-DISEASE PREVENTION
    不详
    LANCET, 1982, 2 (8302): : 803 - 804
  • [23] METAANALYSIS OF THERAPEUTIC TRIALS OF PRIMARY PREVENTION OF ISCHEMIC-HEART-DISEASE WITH LIPID LOWERING DRUGS
    CUCHERAT, M
    BOISSEL, JP
    COLLET, JP
    ARCHIVES DES MALADIES DU COEUR ET DES VAISSEAUX, 1992, 85 : 105 - 108
  • [24] Prevention of coronary heart diseases and lipid-lowering therapy in Japan
    Saito, Y
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2000, 2 (0D) : D49 - D50
  • [25] Coronary heart disease benefits from blood pressure and lipid-lowering
    Sever, Peter S.
    Poulter, Neil R.
    Mastorantonakis, Stylianos
    Chang, Choon Lan
    Dahlof, Bjorn
    Wedel, Hans
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2009, 135 (02) : 218 - 222
  • [27] Landmark Lipid-Lowering Trials in the Primary Prevention of Cardiovascular Disease
    Chrispin, Jonathan
    Martin, Seth S.
    Hasan, Rani K.
    Joshi, Parag H.
    Minder, C. Michael
    McEvoy, John W.
    Kohli, Payal
    Johnson, Amber E.
    Wang, Libin
    Blaha, Michael J.
    Blumenthal, Roger S.
    CLINICAL CARDIOLOGY, 2013, 36 (09) : 516 - 523
  • [28] Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy
    Isles, CG
    Paterson, JR
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2000, 93 (09) : 567 - 574
  • [29] Primary prevention of cardiovascular disease: Implications of lipid-lowering trials
    Pedersen, TR
    JOURNAL OF HYPERTENSION, 1996, 14 : S195 - S200
  • [30] RANDOMIZED CLINICAL-TRIALS IN HEART-DISEASE - IN REPLY
    YUSUF, S
    WITTES, J
    FRIEDMAN, L
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1989, 261 (20): : 2953 - 2954